At one time, the history of the United States weight loss market has been dominated by a single product such as new GLP-1 weight loss drugs. US diets have come to them, avoiding commercial weight loss programs such as weight monitoring, mediifast, and retail and MLM meals.
Demand increased in 2023 and 2024 for Ozempic, Wegovy, Saxenda, Muunjaro and Zepbound -with several new drugs coming over the next few years.
The blooming market for GLP-1 drugs attracts doctors, nurses, dietitians, telemedicin services, medical weight loss franchisees, pharmacies and entrepreneurs. The party may soon be over, as the FDA has ended the lack of major drugs.
What do you need to know about the US medical weight loss market
- The value of the US medical weight loss market is estimated to have tripled since 2019, to $ 33.8 billion in 2024. The average annual growth is expected by 2028.
- The market for prescription obesity drugs rose from $ 2022 to $ 26.4 billion from $ 2022 to $ 26.4 billion in 2024, as the demand for new GLP-1 drugs is high. More than 8% of Americans are estimated to use them.
- The number of weight loss surgeries has been reduced by 25% since 2022 to 211,000, as Americans have chosen new drugs. This market segment is worth $ 5.29 billion.
- The hospitals had mixed records of weight loss programs. Only 29% (about 1,400) of the Nation’s hospitals provide some form of weight loss program or non -surgical program.
- Medical weight loss programs represented 11.7% of the United States’ total weight loss market in 2022, but this share predicts 36% by 2028.
- Prescription weight loss drugs have stolen high market share from commercial weight loss companies, meal replacement market, health clubs, a bariatric surgery market and much more.
- It is estimated that the 11 most important medical weight loss franchises and regional chains generate $ 264 million a year. Most franchises do not grow.
Where can you know more
For deeper information please look at the new report The US Medical Weight Loss Market: Impact of GLP-1s on doctors, hospitals, clinics and franchise By Marketdata, which shows a complete picture of the market, in one place, with extensive primary research.
About the author: John Larosa is president of Marketdata LLC and author of the 100+ industry and market research. His research appears on the most popular media, including ABC, CNN, FOX, ForbesTo USA todayTo The Wall Street JournalTo The New York Timesand various commercial journals.